Fmr LLC Biomea Fusion, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Fmr LLC holds 5,391,566 shares of BMEA stock, worth $46.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,391,566

Previous 5,355,867 0.67%

Holding current value

$46.9 Million

Previous $80.1 Million 69.7%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.14 - $15.3 $147,793 - $546,194	35,699 Added 0.67%	5,391,566 $24.3 Million
Q4 2023 Feb 13, 2024	BUY	$8.37 - $19.8 $97,728 - $231,184	11,676 Added 0.22%	5,355,867 $77.8 Million
Q3 2023 Nov 13, 2023	BUY	$13.44 - $23.02 $457,309 - $783,278	34,026 Added 0.64%	5,344,191 $73.5 Million
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $57.1 Million - $110 Million	2,637,143 Added 98.66%	5,310,165 $117 Million
Q1 2023 May 11, 2023	BUY	$6.8 - $32.35 $15.4 Million - $73.3 Million	2,265,785 Added 556.38%	2,673,022 $82.9 Million
Q4 2022 Feb 13, 2023	SELL	$6.3 - $11.6 $873,047 - $1.61 Million	-138,579 Reduced 25.39%	407,237 $3.43 Million
Q3 2022 Nov 10, 2022	SELL	$9.51 - $13.61 $3.94 Million - $5.64 Million	-414,644 Reduced 43.17%	545,816 $5.34 Million
Q2 2022 Aug 12, 2022	BUY	$3.0 - $12.03 $45 - $180	15 Added 0.0%	960,460 $11.5 Million
Q1 2022 May 13, 2022	BUY	$4.39 - $9.03 $2.74 Million - $5.64 Million	624,582 Added 185.96%	960,445 $4.28 Million
Q3 2021 Nov 15, 2021	SELL	$10.0 - $15.99 $30,000 - $47,970	-3,000 Reduced 0.89%	335,863 $4.02 Million
Q2 2021 Aug 13, 2021	BUY	$13.65 - $20.93 $4.63 Million - $7.09 Million	338,863 New	338,863 $5.29 Million

Others Institutions Holding BMEA

# of Institutions

120

Shares Held

17.9M

Call Options Held

978K

Put Options Held

286K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $255M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account